Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 19, 2026
Reporting Period: Specific event date (January 19, 2026)
This filing reports a corporate governance action taken by the Board of Directors regarding the Company's By-laws. It is not a periodic financial report (e.g., 10-K or 10-Q) and does not cover a fiscal quarter or year.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific corporate event and does not contain financial performance data.
Material Changes
By-laws Amendment: On January 19, 2026, the Board of Directors approved an amendment to the Company's Amended and Restated By-laws. The amendment reduces the quorum requirement for stockholder meetings from a majority to one-third (1/3) of the shares of capital stock entitled to vote. The amendment was effective immediately upon adoption.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the description of the By-laws Amendment is qualified in its entirety by reference to the full text filed as Exhibit 3.1.
Risks and Contingencies: No specific risks, contingencies, or unusual items are disclosed in this filing.
Guidance: No financial guidance or outlook is provided in this document.
Key Facts for Investor Verification
- Verify the full text of the By-laws Amendment in Exhibit 3.1 to understand any additional provisions or implications.
- Confirm the impact of the reduced quorum requirement (from majority to one-third) on future stockholder meeting dynamics and potential governance outcomes.
- Note that this filing does not contain updated financial results; investors should refer to the most recent 10-K or 10-Q for financial health.